Detection and Genotyping of Human Papillomavirus in Self-Obtained Cervicovaginal Samples by Using the FTA Cartridge: New Possibilities for Cervical Cancer Screening

Charlotte H. Lenselink,1 Roosmarie P. de Bie,1 Dennis van Hamont,1 Judith M. J. E. Bakkers,2 Wim G. V. Quint,3 Leon F. A. G. Massuger,1 Ruud L. M. Bekkers,1 and Willem J. G. Melchers2*

Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands1; Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands2; and DDL Diagnostic Laboratory, Voorburg, The Netherlands3

Received 9 February 2009/Returned for modification 24 April 2009/Accepted 17 June 2009

This study assesses human papillomavirus (HPV) detection and genotyping in self-sampled genital smears applied to an indicating FTA elute cartridge (FTA cartridge). The study group consisted of 96 women, divided into two sample sets. All samples were analyzed by the HPV SPF10-Line Blot 25. Set 1 consisted of 45 women attending the gynecologist; all obtained a self-sampled cervicovaginal smear, which was applied to an FTA cartridge. HPV results were compared to a cervical smear (liquid based) taken by a trained physician. Set 2 consisted of 51 women who obtained a self-sampled cervicovaginal smear at home, which was applied to an FTA cartridge and to a liquid-based medium. DNA was obtained from the FTA cartridges by simple elution as well as extraction. Of all self-obtained samples of set 1, 62.2% tested HPV positive. The overall agreement between self- and physician-obtained samples was 93.3%, in favor of the self-obtained samples. In sample set 2, 25.5% tested HPV positive. The overall agreement for high-risk HPV presence between the FTA cartridge and liquid-based medium and between DNA elution and extraction was 100%. This study shows that HPV detection and genotyping in self-obtained cervicovaginal samples applied to an FTA cartridge is highly reliable. It shows a high level of overall agreement with HPV detection and genotyping in physician-obtained cervical smears and liquid-based self-samples. DNA can be obtained by simple elution and is therefore easy, cheap, and fast. Furthermore, the FTA cartridge is a convenient medium for collection and safe transport at ambient temperatures. Therefore, this method may contribute to a new way of cervical cancer screening.

Infection with human papillomavirus (HPV) is a necessary event in the multistep process of cervical carcinogenesis (17, 27). As a result, the clinical value of HPV testing has been well established (1, 3, 5, 6, 10, 11). In the United States, the Food and Drug Administration has authorized a high-risk HPV (HR-HPV) assessment for primary screening in women aged 30 and older. This is in addition to regular cytological screening as well as for the triage of smears of atypical cells of undetermined significance. In The Netherlands, additional HR-HPV testing has been approved and recommended in all follow-up smears after the detection of a first-time borderline or mild dysplasia smear. The beneficial effect of HPV testing will most likely increase in case HR-HPV assessment replaces cytology as primary screening tool (1, 3, 6, 11).

Regarding (HR-)HPV testing, material from vaginal lavages or self-sampling brushes has proven to be highly representative for the cervical (HR-)HPV status (8, 12, 13, 18, 22, 29). In addition, cervicovaginal self-obtained samples have repetitively been proven to be as reliable as physician-taken samples (19, 20). Subsequently, several studies have shown that self-sampling for HPV testing was highly acceptable to women, although some women were concerned about performing the test properly (13, 28). HR-HPV testing on self-sampled materials might be a promising opportunity to increase the efficacy of population-based screening programs worldwide (8, 12, 18, 24). Cervicovaginal self-sampling may be an easy, accessible, user-friendly, and time-saving alternative for the physician-based collection of cervicovaginal material (13, 28).

In the Dutch cervical screening program, approximately 70% of the women who are invited actually take part. Tragically, half of the cervical carcinomas are diagnosed in the remaining group of nonresponders (7, 18, 21). Cervical cancer incidence would decrease significantly if these nonresponders could be reached (5, 6). Several studies have shown that nonresponders actually do take part in self-sampling studies (4, 8, 18). Self-sampling is a less-costly and less-invasive collection method (20). Self-sampled material could be more easily obtained in populations that are difficult to reach and in settings with limited resources, facilitating the introduction of organized HPV-based cervical screening programs in developing countries as well.

However, the vast majority of studies assessing self-sampling have used liquid-based storage and transport media (4, 8, 18, 22). Since these solutions can be inflammable, hazardous, and potentially infectious, careful handling is required and regular mailing may even not be allowed. This severely hampers the introduction of cervicovaginal self-sampling methods. Dried
between September and October 2008, 45 women were re-
sampled. The study group consisted of 96 women, divided into two sample sets (Fig. 3). Sample set 1. Between September and October 2008, 45 women were re-
cruited at the Department of Obstetrics and Gynecology of the Radboud Uni-
versity Nijmegen Medical Centre, The Netherlands. These participants visited 
the gynecologist for follow-up after diethylstilbestrol exposition in utero, treat-
ment of cervical dysplasia, or follow-up after two borderline or mild dysplasia
showed less than 1% false negative samples (15).

In this study, we have assessed the use of self-sampled cer-
vicovaginal smears applied to a new FTA cartridge, i.e., the 
Whatman indicating FTA elute cartridge (Fig. 1 and 2) which 
allows easy storage and transport, as the virus is denaturized 
upon application. Additionally, the cartridge overcomes the 
uncertainty of women about performing the procedure prop-
erly, as it has an indicating dye which changes from purple to 
white when a (genital) sample is applied. Furthermore, we 
assessed the novel method of direct HPV DNA elution without 
requiring further purification.

MATERIALS AND METHODS
The study group consisted of 96 women, divided into two sample sets (Fig. 3). Sample set 1. Between September and October 2008, 45 women were re-
cruited at the Department of Obstetrics and Gynecology of the Radboud Uni-
versity Nijmegen Medical Centre, The Netherlands. These participants visited 
the gynecologist for follow-up after diethylstilbestrol exposition in utero, treat-
mant of cervical dysplasia, or follow-up after two borderline or mild dysplasia

smears. The median age was 38 years (standard deviation, 6.85 years; range, 23 to 51 years).

All women were asked to self-collect a cervicovaginal sample after having 
received instructions on how to perform the self-sample (verbally, written, and in 
cartoon). In brief, participants were instructed to wash their hands before open-
ing the brush cover (Rovers Viba-Brush; Rovers Medical Devices B.V., Oss, The 
Netherlands), to hold the brush by the end of the handle, to insert the brush 
approximately 7 cm into the vagina (similar to inserting a tampon), and to gently 
turn the brush five times. Subsequently, the brush was applied to the FTA 
cartridge (Whatman indicating FTA elute cartridge; catalog number WB 659223; 
GE Healthcare, United Kingdom) (Fig. 1 and 2). The FTA cartridge was air 
dried. After self-sampling, a vaginal speculum was inserted and a physician 
obtained a regular cervical smear using a Rovers Cervex-Brush (Rovers Medical 
Devices B.V., Oss, The Netherlands) that was rinsed in a ThinPrep vial (Cytyc 
Corp., Boxborough, MA). Regular liquid-based cytological (LBC) examination 
was performed, and 0.5 ml of LBC homogenized medium was used for HPV 
assessment.

In order to assess the samples anonymously, all self-obtained samples and 
cervical LBC samples were provided with an unique patient code before they 
were sent to the laboratory. Sample set 2. Sample set 2 consisted of 51 healthy participants who were 
randomly recruited from a prospective self-sampling study of HPV prevalence, 
iccidence, and clearance among 2,065 unscreened women between 18 and 29 
years of age (15). All women were asked to self-collect a cervicovaginal sample 
in the privacy of their own home. Women received an explanatory letter, an 
informed consent form, and a self-sample kit by mail. The self-sample kit was 
provided with an anonymous code to ensure privacy. The self-sample kit con-
tained a collection device (a small brush packaged in an individual sterile cover; 
Rovers Viba-Brush; Rovers Medical Devices B.V., Oss, The Netherlands), an 
FTA cartridge (Whatman indicating FTA elute cartridge; catalog number WB 
659223; GE Healthcare, United Kingdom) (Fig. 1 and 2), a collection tube 
containing medium (SurePath; Tripath Imaging, Inc., Burlington, NC), instruc-
tions how to perform the cervicovaginal self-sample (written and in cartoon), and 
a return package consisting of a leakproof seal bag, absorption sheet, and a 
reclapsible plastic return envelope (Easyslider; Transposafe Systems Holland 
B.V., Sassenheim, The Netherlands). Except for the fact that they used an 
additional liquid-based medium, the instructions of how to perform the self-
sample were similar to the instructions described above. In brief, participants 
were instructed to first apply the self-sample on the FTA cartridge and to 
subsequently place the top of the brush in the collection tube. The collection tube 
was closed and enclosed in the seal bag. Finally, the collection tube was placed 
in the return envelope together with the dried FTA cartridge and sent to the 
Department of Obstetrics and Gynecology for further processing and HPV 
assessment at the Department of Medical Microbiology. The samples were 
stored at room temperature. In the original study of the 2,065 women, a control 
for sample sufficiency, i.e., detection of human beta-globin, was performed and 
showed less than 1% false negative samples (15).
The self-sampling material on the FTA cartridge was compared to the self-sampling material stored in the liquid-based medium (Fig. 3).

**Specimen preparation LBC.** For isolation of DNA from cervical scrapes in LBC medium, the MagNAPure LC isolation station (Roche Diagnostics GmbH, Roche Applied Science, Mannheim, Germany) was used; 500 μl of material was isolated using the MagNAPure LC total nucleic acid isolation kit (Roche Diagnostics GmbH, Roche Molecular Biochemicals, Mannheim, Germany), as described by the manufacturer. With each set of 28 cervical scrape samples, four negative controls were included. Nucleic acid was resuspended in a final volume of 50 μl; 10 μl was used for PCR analysis (25).

**Specimen preparation of the indicating FTA elute cartridge.** The indicating FTA elute matrix contains an indicating dye that changes from purple to white upon application of a colorless sample such as a cervicovaginal swab. The FTA cartridges were punched using a sterilized perforator specifically designed for the FTA cartridges (3-mm Harris Uni-Core device; Whatman). The sample amount varied between samples, and to optimize the number of punches to cover this variation, pilots were performed using a different number of punches. For this study, only three punches were considered to compare DNA elution and extraction, as well as individual genotypes.

The FTA elute matrix is chemically treated with proprietary reagents that lyse cells upon contact, causing the release of nucleic acids. DNA was recovered from the FTA elute matrix through a simplified elution process using heat and water. Inhibitory components, such as hemoglobin, are retained on the FTA elute matrix through a simplified elution process using heat and water.

**Elution.** The three punches were transferred into a 1.5-ml Microfuge tube and 1.500 μl of sterile water was added to the punches and immediately pulse vortexed three times for a total of 5 s. The water was removed with a sterile fine-tip pipette. Fifty microliters of sterile water was added to the punches, and the tube was transferred to a heating block at 95°C for 30 min. At the end of the incubation period, the sample was removed from the heating block and pulse vortexed approximately 60 times. It was additionally centrifuged for 30 s, and the eluted DNA was placed into a new microcentrifuge tube with a pipette. The eluted DNA was stored at −80°C.

Finally, 10 μl of the eluate was used for PCR analysis.

**Isolation.** For additional comparison, DNA was extracted from three other punches using the Qiagen DNeasy tissue kit (Qiagen Inc., Valencia, CA), as described by the manufacturer.

Subsequently, HPV DNA assessment was performed identically as for the LBC specimens, as described below. All HPV tests were performed by laboratory assistants unaware of the cytological status and the results from the comparative HPV detection tests.

**HPV detection and genotyping.** Broad-spectrum HPV DNA amplification was performed using a short-PCR-fragment assay (HPV SPF10-Line Blot 25; Labo Bio-medical Products B.V., Rijswijk, The Netherlands). This assay amplifies a 65-bp fragment of the L1 open reading frame and allows detection of a broad range of HR, low-risk (LR), and possible HR-HPV genotypes (16).

Twenty-eight oligonucleotide probes which recognize 25 different types were tailed with poly(dT) and immobilized as parallel lines to membrane strips (Labo Bio-medical Products B.V., Rijswijk, The Netherlands). The HPV genotypes detectable are HR-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, and 68/73 and two probable HR-HPV types (53 and 66). Samples that tested positive using the DNA enzyme immunoassay but showed no results on the LiPA strip were considered to be HPV “X” type, i.e., genotypes not available on the LiPA strip. LR-HPV types were defined as HPV type 6, 11, 34, 40, 42, 43, 44, 54, 55, 58, 70, 73, and X. The HPV genotyping assay was performed as described previously (26). The LiPA strips were visually inspected and interpreted using the provided reference guide.

**Study design.** All samples were assessed for HPV genotyping using the HPV SPF10-Line Blot 25 assay.

For the first sample set, the self-sampled material on the FTA cartridge was compared to a liquid-based cervical smear obtained for diagnostic purposes by a trained physician in the outpatient clinic. Additionally, as HPV DNA elution is a novel method to obtain HPV DNA from an FTA elute cartridge, results of DNA elution were compared to results from HPV DNA extraction (Fig. 3).

In the second sample set, the self-sampled material stored in liquid-based solution was compared to self-sampled material on the FTA cartridge. Again, results of DNA elution and extraction from the FTA cartridge were compared (Fig. 3). In the original study population of sample set 2 (n = 2,065), detection of beta-globin was used as a control for sample sufficiency and showed less than 1% false negatives.

Comparing the presence of HR-HPV between the two samples, results were termed concordant or discordant based on the following definitions. If analyses showed identical genotypes in both samples, the results were termed concordant. Genotyping results were termed discordant when no similarities in the genotypes existed.

This study was approved by the local medical ethics committee. All participants provided an informed consent.

---

**FIG. 3. Study design.**
TABLE 1. HPV detection by SPF10-Line Blot 25 for corresponding genital self-obtained smears and physician-obtained cervical smears (sample set 1)\textsuperscript{a}

<table>
<thead>
<tr>
<th>Sample no.</th>
<th>HPV detection using physician-obtained samples (LBC)</th>
<th>HPV detection using self-obtained sample (FTA cartridge)</th>
<th>HPV accordance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DNA extraction</td>
<td>HR</td>
<td>LR</td>
</tr>
<tr>
<td>1</td>
<td>52</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>51</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>18, 31</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>16</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>53</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>16</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>6</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>N</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>16, 66</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>N</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>12</td>
<td>66</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>13</td>
<td>X</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>14</td>
<td>59</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>15</td>
<td>39</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>16</td>
<td>42</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>17</td>
<td>16</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>18</td>
<td>N</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>19</td>
<td>51</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>20</td>
<td>68, 70</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>21</td>
<td>51</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>22</td>
<td>X</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>23</td>
<td>6, 51, 58</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>24</td>
<td>58</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>25</td>
<td>31</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>26</td>
<td>70</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>27</td>
<td>6</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>28</td>
<td>X</td>
<td>–</td>
<td>+</td>
</tr>
<tr>
<td>29–45</td>
<td>N</td>
<td>N</td>
<td>N</td>
</tr>
</tbody>
</table>

\textsuperscript{a} HR-HPV types (HR) were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, and 68/73; probable HR-HPV types were 53 and 66. LR-HPV types (LR) were 6, 11, 34, 40, 42, 43, 44, 55, 58, 70, 74, and X. c, concordant results; d, discordant results; N, HPV negative; –, negative; +, positive.

Statistics. All data were analyzed using SPSS version 16.0 for Windows (Chicago, IL). Agreement was measured by absolute agreement and Cohen’s kappa statistics, a measure of the agreement between two methods that is in excess of that due to chance.

RESULTS

The study group consisted of 96 women between 18 and 51 years of age. The results of the two sample sets are described separately, since sample set 2 consisted of healthy unscreened women and sample set 1 consisted of women with a higher risk of an HPV infection than in the general population as they had initially been referred to the gynecologist for cervical follow-up for several reasons.

Sample set 1. The median age of the 45 women in sample set 1 was 38 years (standard deviation, 6.85 years; range, 23 to 51 years).

Cervicovaginal self-obtained sample versus physician-obtained cervical smear. Of the 45 self-collected cervicovaginal samples on the FTA cartridges, 62.2% (n = 28) tested positive for one or more HPV genotypes. This high prevalence was expected due to the nature of the follow-up. Of these 28 samples, 25 also tested positive for HPV in the cervical smear sample obtained by the physician.

Of the 28 HPV-positive samples, 19 samples showed similar types, 5 samples showed an additional genotype (sample no. 2, 5, 9, 16, and 25) (Table 1), and 4 samples showed a different genotype (sample no. 8, 10, 18, and 20) (Table 1). The overall agreement for HPV positivity between self-sampling and the cervical smear taken by the physician was 93.3% (kappa value, 0.86; 95% confidence interval [CI], 0.713 to 1.013).

Concordance and discordance of HR-HPV. Table 1 shows a summary of the genotypes per sample set as well as the concordance and discordance for HR-HPV. Taking the samples of all 45 women into account, 42 samples (93.3%) were concordant and 3 samples (6.7%) were discordant for HR-HPV presence. In these three samples, the physician-obtained smear did not contain a HR-HPV type in contrast to the self-obtained sample (sample no. 8, 16, and 18) (Table 1).

Of the 42 concordant samples, 29 showed no HR-HPV DNA in both self- and physician-obtained samples. In 20 of the 45 (44.4%) self-obtained samples, one or more HR-HPV types were detected; 17 patients also tested HR-HPV positive in the cervical smears obtained by the physician. The overall agreement for HR-HPV positivity was 93.3% (kappa value, 0.86; 95% CI, 0.713 to 1.013).

Concordance and discordance of LR-HPV. In 13 of the 45 (28.9%) self-obtained samples, one or more LR-HPV types were detected; 10 patients also tested LR-HPV positive in the cervical smears obtained by the physician. The overall agreement for LR-HPV positivity was 93.3% (kappa value, 0.83; 95% CI, 0.635 to 1.016).

Table 1 shows a summary of the genotypes per sample set as
well as the concordance and discordance for LR-HPV. Taking the samples of all 45 women into account, 42 samples (93.3%) were concordant and 3 samples (6.7%) were discordant for LR-HPV. Taking all samples (100%) also tested HR-HPV positive on the FTA cartridge and liquid-based medium was 100% (kappa value, 1.0; 95% CI, 1.0 to 1.0), indicating the reliability of this procedure (Table 1).

Concordance and discordance of HR-HPV. One or more HR-HPV types were detected in seven of the liquid-based stored self-obtained samples (13.7%) versus seven on the FTA cartridges (Table 2). However, not all samples showed similar types, resulting in only five concordant LR-HPV types. The overall agreement for LR-HPV positivity between FTA cartridge and liquid-based medium was 96.1% (kappa value, 0.83; 95% CI, 0.609 to 1.059).

DNA elution versus DNA extraction. In sample set 2, HPV DNA yielded from the self-obtained material on the FTA cartridge by DNA elution was again compared to DNA yielded from the FTA cartridge by extraction. The results showed an overall agreement of 100% (kappa value, 1.0; 95% CI, 1.0 to 1.0).

**DISCUSSION**

HPV testing in cervical cancer screening has a beneficial effect in patient management and can increase the success rate of population-based screening programs in reducing cervical cancer incidence (1, 3, 6, 11). Regarding HR-HPV testing, cervicovaginal self-obtained samples have repetitively been proven to be as reliable as physician-obtained samples (19, 20). This present study underlines the reliability of using cervicovaginal self-samples for HR-HPV testing.

However, despite differences in self-sampling methods, many previous studies have used liquid-based sample storage and transport media. Use of these solutions may result in a delay or inability to implement at-home self-sampling of population-based screening nonresponders because of a number of reasons. For example, one reason is the high cost due to legislations for these potentially hazardous liquid-based techniques, which require difficult and therefore expensive logistics. An alternative for the transport of potentially hazardous solutions could be storage on filter papers, i.e., FTA cartridges. These FTA cartridges, for example, are less prone to contamination and are therefore easy to handle. For instance, filters have

---

**TABLE 2. HPV detection by SPF10-Line Blot 25 for corresponding genital self-obtained smears with liquid-based medium versus FTA cartridge (sample set 2)**

<table>
<thead>
<tr>
<th>Sample no.</th>
<th>HPV detection using self-samples (LBC)</th>
<th>HPV detection using self-samples (FTA cartridge)</th>
<th>HPV accordance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DNA extraction</td>
<td>HR</td>
<td>LR</td>
</tr>
<tr>
<td>1</td>
<td>18, 51, 54, 68</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>56</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>3</td>
<td>X</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>X</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>5</td>
<td>42, 51, 54</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>52</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>7</td>
<td>X</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>8</td>
<td>16</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>9</td>
<td>16, 45, 51</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>10</td>
<td>68</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>11</td>
<td>31</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>12</td>
<td>39, 54</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>13</td>
<td>54</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>14–51</td>
<td>N</td>
<td>−</td>
<td>−</td>
</tr>
</tbody>
</table>

*HR-HPV types (HR) were 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 59, and 68/73; probable HR-HPV types were 53 and 66. LR-HPV types (LR) were 6, 11, 34, 40, 42, 43, 44, 54, 55, 58, 70, 74, and X. c, concordant; d, discordant; N, HPV negative; −, negative; +, positive.*
been used for decades in the postnatal screening of certain congenital disorders and diseases. The air-dried samples showed stability at room temperature for months, up to years (9). Furthermore, at-home collection for HIV testing on filter papers has been considered feasible and acceptable in a high-risk cohort. Additionally, also viral load and genotypic resistance assessments in applied whole blood and plasma of HIV-positive patients appear to be possible (2, 23).

To compare the transport media used in this study, it would be ideal if all conditions across the groups were equal. However, as we are particularly interested in whether the results of HPV detection in cervicovaginal self-obtained samples are comparable to the results of HPV detection in physician-taken cervical smears, the “golden standard,” despite or precisely because the conditions differ, we think it is important to compare the self-sampling method with the “regular” physician-taken smear as a proof of principle. This study shows a high level of overall agreement of HPV detection and genotyping between physician-obtained cervical smears which are applied to a liquid-based medium and self-obtained cervicovaginal samples that are subsequently applied to an FTA cartridge. Additionally, all HR-HPV-positive physician-obtained smears were HR-HPV positive in the cervicovaginal self-samples as well. Besides the reliability of the FTA cartridge regarding HR-HPV testing, its unique properties make it easy to handle. For instance, the air-dried FTA cartridges showed stability at room temperature for months. Furthermore, the uncertainty about performing the self-sampling procedure properly will be overcome since the indicating FTA cartridge has an indicating dye which changes upon application of the sample. Furthermore, the contamination risk is reduced as the virus is denatured upon application, making it biohazard free and safe for transport by mail. This allows cervical or self-obtained genital samples to be added to this FTA cartridge and sent to designated central laboratories for analysis. Even more important, by using the FTA cartridge, processing costs will be low as DNA is eluted by a simple method using only water and heat, without requiring expensive DNA extraction. Besides the use in existing screening programs, usage of the FTA cartridge could simplify the introduction of organized HPV-based cervical screening programs in developing countries as well.

It has been shown that self-sampling methods are unsuitable for cytological analysis (8, 18). To complete the diagnosis for the individual HR-HPV-positive patient, a subsequent physician-obtained smear ought to be performed. Preferably, this is done solely in women who are persistently HR-HPV positive. Whether the self-sampling women are willing to have an additional cervical smear taken in case of HR-HPV persistence has not yet been studied.

Since cervicovaginal self-sampling could be an easily accessible and user-friendly method, women not participating in the screening program due to fear or other reasons might be interested to actually participate since this technique could be applicable to at-home self-sampling. Therefore, the introduction of cervicovaginal self-sampling will probably increase the participation rate (8, 12, 18, 24). Recently, Bais et al. showed that the active response to self-sampling in population-based screening nonresponders was significantly higher than the active response to an extra recall for conventional cytology (4).

For HPV detection and genotyping, we used the HPV SPF16-Line Blot 25. This assay has previously shown high concordance with various other systems (25, 26). This indicates the suitability of the FTA cartridge for various other HPV detection and genotyping systems like the Roche Amplicor and linear array assays. Preliminary studies indeed showed an excellent concordance (data not shown). However, further study may be needed to assess genital self-sampled FTA cartridges using other commercially available HPV detection tests with lower analytical sensitivity (e.g., Hybrid Capture II). Additionally, since this was a pilot study and sample sizes were small, further research should be conducted. Furthermore, since not all samples were checked for specimen sufficiency (e.g., beta-globin), future research should include a measure for sample sufficiency.

In conclusion, the results of HPV detection and genotyping on self-sampled cervicovaginal samples using a Rovers Viba-Brush and the Whatman indicating FTA elite cartridge are highly representative for the cervical HPV status.

Furthermore and equally important, this study shows that elution of DNA from the Whatman indicating FTA elite cartridge, without the necessity of DNA extraction procedures, is a fast, cheap, and reliable method. The Whatman indicating FTA elite cartridge technique is a convenient medium for collection, as the color of the FTA cartridge changes after application of the self-sampled material, confirming proper use. Additionally, the FTA cartridges can be stored at ambient temperatures for months, and since the method is nonhazardous, the samples are allowed to be sent by regular mail. This suggests that this method might be applicable to at-home self-sampling in population-based screening nonresponders, as well as for the introduction of primary HPV-based cervical cancer prevention and for establishing cervical cancer screening programs in developing countries.

ACKNOWLEDGMENTS

This study was partially supported by GlaxoSmithKline. The funder of this study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Concerning this paper, no conflict of interest exists.

We thank Nel H. T. H. Struijk-van der Zanden for the logistical support critical to this study, Furthermore, the Delft Diagnostic Laboratory kindly provided the HPV SPF16-Line Blot 25 genotyping test and detection reagents, Rovers Medical Devices B.V. supplied the Rovers Cervix-Brush and Rovers Viba-Brush, and GE Healthcare provided the Whatman indicating FTA elite cartridges.

REFERENCES


